Xiaohua Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5596442/publications.pdf

Version: 2024-02-01

759055 752573 30 453 12 20 h-index citations g-index papers 33 33 33 685 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus–infected mongolians. Hepatology, 2017, 66, 1739-1749.	3.6	74
2	Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study. Emerging Microbes and Infections, 2022, 11, 639-647.	3.0	36
3	The delivery of HBcAg via Tat-PTD enhances specific immune response and inhibits Hepatitis B virus replication in transgenic mice. Vaccine, 2010, 28, 3913-3919.	1.7	30
4	Tripartite motif-containing protein 7 regulates hepatocellular carcinoma cell proliferation via the DUSP6/p38 pathway. Biochemical and Biophysical Research Communications, 2019, 511, 889-895.	1.0	30
5	Thresholds of Glycemia and the Outcomes of COVID-19 Complicated With Diabetes: A Retrospective Exploratory Study Using Continuous Glucose Monitoring. Diabetes Care, 2021, 44, 976-982.	4.3	30
6	<p>HOXA10 knockdown inhibits proliferation, induces cell cycle arrest and apoptosis in hepatocellular carcinoma cells through HDAC1</p> . Cancer Management and Research, 2019, Volume 11, 7065-7076.	0.9	25
7	Hepatitis D Viremia Among Injection Drug Users in San Francisco. Journal of Infectious Diseases, 2018, 217, 1902-1906.	1.9	24
8	Incorporation of Urinary Neutrophil Gelatinase-Associated Lipocalin and Computed Tomography Quantification to Predict Acute Kidney Injury and In-Hospital Death in COVID-19 Patients. Kidney Diseases (Basel, Switzerland), 2021, 7, 120-130.	1.2	24
9	<p>Plumbagin inhibits proliferation and induces apoptosis of hepatocellular carcinoma by downregulating the expression of SIVA</p> . Drug Design, Development and Therapy, 2019, Volume 13, 1289-1300.	2.0	21
10	Hepatitis D virus infection, cirrhosis and hepatocellular carcinoma in The Gambia. Journal of Viral Hepatitis, 2019, 26, 738-749.	1.0	20
11	The modification of Tapasin enhances cytotoxic T lymphocyte activity of intracellularly delivered CTL epitopes & amp;lt;italic>via cytoplasmic transduction peptide. Acta Biochimica Et Biophysica Sinica, 2013, 45, 203-212.	0.9	16
12	Tapasin modification on the intracellular epitope HBcAg18â€"27 enhances HBV-specific CTL immune response and inhibits hepatitis B virus replication in vivo. Laboratory Investigation, 2014, 94, 478-490.	1.7	14
13	Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice. Immunobiology, 2016, 221, 813-821.	0.8	12
14	Molecular epidemiology and clinical characteristics of hepatitis delta virus (HDV) infected patients with elevated transaminases in Shanghai, China. BMC Infectious Diseases, 2020, 20, 565.	1.3	12
15	Dendritic cell-based vaccination with lentiviral vectors encoding ubiquitinated hepatitis B core antigen enhances hepatitis B virus-specific immune responsesin vivo. Acta Biochimica Et Biophysica Sinica, 2015, 47, 870-879.	0.9	11
16	Enhancement of cytotoxic T lymphocyte activity by dendritic cells loaded with Tat-protein transduction domain-fused hepatitis B virus core antigen. Acta Biochimica Et Biophysica Sinica, 2008, 40, 996-1004.	0.9	9
17	FDG PET/CT Showing Erythema Nodosum Associated With Tuberculous Lymphadenitis. Clinical Nuclear Medicine, 2013, 38, 992-993.	0.7	8
18	Correlation between low tapasin expression and impaired CD8+ T-cell function in patients with chronic hepatitis B. Molecular Medicine Reports, 2016, 14, 3315-3322.	1.1	8

#	Article	lF	CITATIONS
19	An engineered novel lentivector specifically transducing dendritic cells and eliciting robust HBV-specific CTL response by upregulating autophagy in T cells. Cell Cycle, 2018, 17, 1220-1234.	1.3	6
20	Fusion protein of tapasin and hepatitis B core antigen 18-27 enhances T helper cell type $1/2$ cytokine ratio and antiviral immunity by inhibiting suppressors of cytokine signaling family members $1/3$ in hepatitis B virus transgenic mice. Molecular Medicine Reports, 2014, 9, 1171-1178.	1.1	5
21	Ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances HBV-specific humoral and CTL immune responses in vivo. International Immunopharmacology, 2014, 23, 1-7.	1.7	5
22	Advances in 3D cell culture for liver preclinical studies. Acta Biochimica Et Biophysica Sinica, 2021, 53, 643-651.	0.9	5
23	Vaccination with ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances the hepatitis B virus-specific cytotoxic T-lymphocyte immune response and inhibits hepatitis B virus replication in transgenic mice. Molecular Medicine Reports, 2015, 12, 3591-3598.	1.1	4
24	Ubiquitin-modified hepatitis B virus core antigen effectively facilitates antigen presentation and enhances cytotoxic T lymphocyte activity via the cytoplasmic transduction peptide in vitro. Molecular Medicine Reports, 2015, 12, 289-296.	1,1	4
25	Role of tripeptidyl peptidase II in MHC class I antigen presentation: Biological characteristics, cellular crosstalk and signaling. Biomedicine and Pharmacotherapy, 2016, 84, 1954-1958.	2.5	4
26	Delivery of Tapasin-modified CTL epitope peptide via cytoplasmic transduction peptide induces CTLs by JAK/STAT signaling pathway & amp; lt; italic & amp; gt; in vivo & amp; lt; / italic & amp; gt;. Acta Biochimica Et Biophysica Sinica, 2018, 50, 181-190.	0.9	4
27	Immunization with lentiviral vector‑modified dendritic cells encoding ubiquitinated hepatitis B core antigen promotes Th1 differentiation and antiviral immunity by enhancing p38 MAPK and JNK activation in HBV transgenic mice. Molecular Medicine Reports, 2018, 18, 4691-4699.	1.1	4
28	Adenovirus vector encoding TPPII ignites HBVâ€specific CTL response by activating autophagy in CD8+ T cell. Journal of Viral Hepatitis, 2022, 29, 178-188.	1.0	3
29	Ubiquitinated Hepatitis D Antigen-Loaded Microvesicles Induce a Potent Specific Cellular Immune Response to Inhibit HDV Replication in Vivo. Microbiology Spectrum, 2021, 9, e0102421.	1.2	3
30	The features comparison between patients in the ICU and general wards and between patients with different outcomes: a 2020 COVID-19 study. Annals of Palliative Medicine, 2021, 10, 672-680.	0.5	2